GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells

GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells

Xuan Wan,1,&ast; Yuting Fang,2,&ast; Jiangzhou Du,1 Shaoxi Cai,1 Hangming Dong1 1Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, People’s Republic of China; 2BSL-3...

Full description

Bibliographic Details
Main Authors:	Wan X, Fang Y, Du J, Cai S, Dong H
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-11-01
Series:	OncoTargets and Therapy
Subjects:	gw4869 emt gefitinib-sensitive nsclc ehsp90α
Online Access:	https://www.dovepress.com/gw4869-can-inhibit-epithelial-mesenchymal-transition-and-extracellular-peer-reviewed-fulltext-article-OTT

Similar Items

Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer
by: Yilin Peng, et al.
Published: (2022-08-01)

The Promotional Effect of GW4869 on <i>C. albicans</i> Invasion and Cellular Damage in a Murine Model of Oral Candidiasis
by: Miaomiao Zhang, et al.
Published: (2022-12-01)

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
by: Xing-Xing Fan, et al.
Published: (2014-03-01)

Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane
by: Kerstin Menck, et al.
Published: (2017-12-01)

Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer Progression
by: Pietro Poggio, et al.
Published: (2021-10-01)

Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial–Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage
by: Minghui Peng, et al.
Published: (2022-05-01)

Extracellular Hsp90α Supports the ePKM2-GRP78-AKT Axis to Promote Tumor Metastasis
by: Shaosen Zhang, et al.
Published: (2022-06-01)

Fasudil Increased the Sensitivity to Gefitinib in NSCLC by Decreasing Intracellular Lipid Accumulation
by: Tingting Liao, et al.
Published: (2022-09-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
by: Jun Li, et al.
Published: (2020-02-01)

Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development
by: Chia-Chi Chen, et al.
Published: (2018-05-01)

Exosomes mediate Zika virus transmission through SMPD3 neutral Sphingomyelinase in cortical neurons
by: Wenshuo Zhou, et al.
Published: (2019-01-01)

Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
by: Chi-Shuan Fan, et al.
Published: (2019-12-01)

High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer
by: Baoyue Huang, et al.
Published: (2022-07-01)

Intraocular delivery of ZIF-90-RhB-GW2580 nanoparticles prevents the progression of photoreceptor degeneration
by: Peipei Cao, et al.
Published: (2023-02-01)

Tick-Borne Flavivirus Inhibits Sphingomyelinase (IsSMase), a Venomous Spider Ortholog to Increase Sphingomyelin Lipid Levels for Its Survival in Ixodes scapularis Ticks
by: Pravesh Regmi, et al.
Published: (2020-06-01)

Inhibiting extracellular vesicles formation and release: a review of EV inhibitors
by: Mariadelva Catalano, et al.
Published: (2020-01-01)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression
by: Ren Shengnan, et al.
Published: (2022-11-01)

Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells
by: Jinjin Shao, et al.
Published: (2024-04-01)

Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
by: Wang Bing, et al.
Published: (2017-06-01)

Extracellular HSP90α Induces MyD88-IRAK Complex-Associated IKKα/β−NF-κB/IRF3 and JAK2/TYK2−STAT-3 Signaling in Macrophages for Tumor-Promoting M2-Polarization
by: Chi-Shuan Fan, et al.
Published: (2022-01-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
by: Yi Xiao, et al.
Published: (2018-06-01)

Antibacterial Activities of Secondary Metabolites Derived from Streptomyces sp. VITGV38 (MCC4869) against Selected Uropathogens
by: Amjad Hussain, et al.
Published: (2023-12-01)

Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells
by: Shaojia Wang, et al.
Published: (2021-05-01)

PNSA, a Novel C-Terminal Inhibitor of HSP90, Reverses Epithelial–Mesenchymal Transition and Suppresses Metastasis of Breast Cancer Cells In Vitro
by: Aotong Zhang, et al.
Published: (2021-02-01)

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC
by: Dongcheng Liu, et al.
Published: (2022-06-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Analysis of Prognostic Factors of 80 Advanced NSCLC Patients Treated with Gefitinib for more than 6 Months
by: Ling DAI, et al.
Published: (2010-11-01)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
by: Zhonghan Zhang, et al.
Published: (2020-06-01)

Pyogenic Granuloma in a Patient on Gefitinib
by: António Fernandes Massa, et al.
Published: (2016-06-01)

The Double-Edged Sword: Conserved Functions of Extracellular Hsp90 in Wound Healing and Cancer
by: Michael W. Hance, et al.
Published: (2014-05-01)

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer
by: Ting He, et al.
Published: (2022-08-01)

AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
by: Yi-Hua Lai, et al.
Published: (2017-11-01)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
by: Zhonghan Zhang, et al.
Published: (2019-11-01)

Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2
by: Yu Zheng, et al.
Published: (2022-02-01)

Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer
by: Moulid Hidayat, et al.
Published: (2019-11-01)

Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells
by: Haiying LI, et al.
Published: (2016-01-01)

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
by: Shaoxing Guan, et al.
Published: (2022-09-01)

Extracellular HSP70 Activates ERK1/2, NF-kB and Pro-Inflammatory Gene Transcription Through Binding with RAGE in A549 Human Lung Cancer Cells
by: Nauana Somensi, et al.
Published: (2017-08-01)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
by: Hongbo Zhao, et al.
Published: (2018-11-01)